Matt Tremblay, PhD
Matt Tremblay, PhD, is the executive advisor for Scripps Research and its drug discovery division, Calibr. Tremblay works closely with the chief executive officer and the interim chief operating officer to create the long term strategic vision for the institute and advance new business development opportunities.
Tremblay played a key role in establishing Calibr in 2012, where he led a team of biologists in the discovery of new therapeutic agents for metabolic, cardiovascular and autoimmune diseases. As Calibr grew to a 100+ employee drug discovery organization, he facilitated the launch of a number of strategic collaborations with major foundations and pharmaceutical companies, and was subsequently promoted to chief operating officer. When Calibr became an affiliate of Scripps Research in 2016, Tremblay took on the additional role of vice president for Business Development at the institute, before being named chief operating officer of the combined institutes in 2018. He shifted into the executive advisor role in early 2023.
Tremblay earned his doctorate in Chemistry at Columbia University. Following postdoctoral work in the laboratory of Peter Schultz, PhD, at Scripps Research, he led a group at the Genomics Institute of the Novartis Research Foundation until joining Calibr.